Skip to content
ATLAS PREP HQ
Research

PNC-27

p53-derived anticancer peptide containing the p53 HDM-2-binding region fused to a membrane-residency sequence

Preclinical anticancer peptide research targeting interactions between p53-derived sequences and HDM-2.

Preclinical Evidence

Route

Subcutaneous only in experimental/vendor-style protocols

Common format

30 mg vial

Research focus

cancer-cell membrane targeting

Evidence level

Preclinical Evidence

Typical cycle

No established human cycle

Research research motifResearch

PNC-27 in 30 seconds

Atlas Fast Read

What it is

p53-derived anticancer peptide containing the p53 HDM-2-binding region fused to a membrane-residency sequence

Why people care

Preclinical anticancer peptide research targeting interactions between p53-derived sequences and HDM-2.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Human safety, tumor selectivity in vivo, pharmacokinetics, immunogenicity, off-target membrane effects, manufacturing, effective dosing, and interaction with standard cancer therapy are all unknown.

Bottom line

PNC-27 is a preclinical oncology concept.

Overview

What is PNC-27?

PNC-27 is p53-derived anticancer peptide containing the p53 HDM-2-binding region fused to a membrane-residency sequence. Preclinical anticancer peptide research targeting interactions between p53-derived sequences and HDM-2.

PNC-27 emerged from p53/HDM-2 anticancer-peptide research in the 1990s and 2000s. The concept is to pair a p53-derived HDM-2-binding sequence with a membrane-active segment to selectively damage cancer-cell membranes.

Mechanism

How it works

The p53-derived segment binds HDM-2 displayed on some cancer-cell membranes, while the attached membrane-active region is proposed to form disruptive pores. This mechanism has been demonstrated preclinically, not in patients.

Research areas

cancer-cell membrane targetingp53/HDM-2selective cytotoxicitypreclinical oncology

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No human clinical trials establish PNC-27 as a cancer treatment. It should be considered a preclinical oncology research peptide, not an alternative to standard cancer therapy.

Preclinical evidence

In vitro and animal studies report selective membrane disruption in cancer cells expressing surface HDM-2, with relative sparing of normal cells. This remains a preclinical anticancer strategy.

Knowledge gaps

Human safety, tumor selectivity in vivo, pharmacokinetics, immunogenicity, off-target membrane effects, manufacturing, effective dosing, and interaction with standard cancer therapy are all unknown.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

No validated human dose exists. community sources displays an experimental 100–500 mcg/day SC titration but explicitly notes that authoritative human dosing does not exist and that safety is unestablished.

Frequency

community sources experimental schedule is once daily; this is not a clinical regimen.

Timing

No established timing requirement.

Route

Subcutaneous only in experimental/vendor-style protocols; preclinical cancer studies use laboratory models.

Cycle length

No established human cycle

Reconstitution

Community reference: 3 mL bacteriostatic water per 30 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid freeze-thaw.

Monitoring

Any cancer-related use belongs in formal oncology care/research with disease-specific imaging, pathology and safety labs. PNC-27 must not substitute for evidence-based cancer treatment.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

There is no human adverse-event profile. As a membrane-active anticancer peptide, off-target cytotoxicity, inflammatory reactions, immunogenicity and organ toxicity are major unresolved concerns.

Contraindications

No human therapeutic use is established. It should not be used outside formal oncology research and must never replace surgery, radiation, chemotherapy, targeted therapy or immunotherapy when indicated.

Interactions

Interactions with chemotherapy, radiation, immunotherapy and targeted agents are unknown. Any combination belongs in formal preclinical/clinical oncology research.

Stacks

Common stacks

No self-directed stack

Cancer therapy combinations require formal oncology research and must not replace evidence-based treatment.

No human combination evidence.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

PNC-27 is a preclinical oncology concept. The membrane-targeting mechanism is interesting, but there is no human cancer-efficacy evidence and no defensible self-treatment protocol. It should never be framed as an alternative to established oncology care.